Brave Warrior Advisors LLC Acquires 724,349 Shares of Elevance Health, Inc. $ELV

Key Points

• Brave Warrior Advisors LLC boosted its stake in Elevance Health by 65.3%, buying 724,349 shares to hold 1,834,002 shares — about 0.83% of the company and valued at roughly $592.6 million, making ELV the firm's largest position (13.8% of its holdings).
• Analysts have trimmed several price targets recently (examples: UBS $400, Bernstein $409, Wells Fargo $391), but the consensus remains a Moderate Buy with an average target of $387.40.
• Elevance beat quarterly EPS estimates ($3.33 vs. $3.10) while revenue slightly missed ($49.31B vs. $49.52B), and the company raised its quarterly dividend to $1.72 (annual $6.88, ~2.4% yield).

Brave Warrior Advisors LLC increased its holdings in Elevance Health, Inc. (NYSE:ELV - Free Report) by 65.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,834,002 shares of the company's stock after purchasing an additional 724,349 shares during the quarter. Elevance Health accounts for 13.8% of Brave Warrior Advisors LLC's holdings, making the stock its biggest position. Brave Warrior Advisors LLC owned about 0.83% of Elevance Health worth $592,603,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Physician Wealth Advisors Inc. boosted its holdings in Elevance Health by 331.6% during the third quarter. Physician Wealth Advisors Inc. now owns 82 shares of the company's stock worth $26,000 after buying an additional 63 shares in the last quarter. Activest Wealth Management increased its holdings in shares of Elevance Health by 66.7% in the third quarter. Activest Wealth Management now owns 85 shares of the company's stock valued at $27,000 after buying an additional 34 shares in the last quarter. Rossby Financial LCC lifted its position in shares of Elevance Health by 110.0% during the 3rd quarter. Rossby Financial LCC now owns 84 shares of the company's stock valued at $28,000 after acquiring an additional 44 shares during the last quarter. Vermillion & White Wealth Management Group LLC boosted its stake in shares of Elevance Health by 94.9% during the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 76 shares of the company's stock worth $30,000 after acquiring an additional 37 shares in the last quarter. Finally, Motco boosted its stake in shares of Elevance Health by 334.8% during the 3rd quarter. Motco now owns 100 shares of the company's stock worth $32,000 after acquiring an additional 77 shares in the last quarter. 89.24% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on ELV shares. UBS Group set a $400.00 target price on Elevance Health in a research report on Thursday, January 29th. Sanford C. Bernstein decreased their price target on Elevance Health from $431.00 to $409.00 and set an "outperform" rating for the company in a research report on Friday, January 30th. Wells Fargo & Company dropped their price target on Elevance Health from $424.00 to $391.00 and set an "overweight" rating on the stock in a research note on Friday, January 30th. Morgan Stanley reduced their price objective on shares of Elevance Health from $359.00 to $352.00 and set an "equal weight" rating for the company in a research note on Wednesday, December 17th. Finally, Barclays decreased their target price on shares of Elevance Health from $404.00 to $393.00 and set an "overweight" rating for the company in a report on Friday, January 30th. Twelve research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Elevance Health currently has a consensus rating of "Moderate Buy" and an average target price of $387.40.

Elevance Health Stock Up 1.3%

NYSE:ELV opened at $291.69 on Friday. The business's fifty day moving average price is $338.25 and its 200 day moving average price is $334.28. The firm has a market capitalization of $64.38 billion, a price-to-earnings ratio of 11.61, a PEG ratio of 1.61 and a beta of 0.51. The company has a current ratio of 1.54, a quick ratio of 1.54 and a debt-to-equity ratio of 0.70. Elevance Health, Inc. has a 1-year low of $273.71 and a 1-year high of $458.75.

Elevance Health (NYSE:ELV - Get Free Report) last released its earnings results on Wednesday, January 28th. The company reported $3.33 earnings per share for the quarter, beating the consensus estimate of $3.10 by $0.23. The company had revenue of $49.31 billion for the quarter, compared to analysts' expectations of $49.52 billion. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.The business's revenue for the quarter was up 9.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $3.84 EPS. Elevance Health has set its FY 2026 guidance at 25.500- EPS. On average, sell-side analysts forecast that Elevance Health, Inc. will post 33.96 earnings per share for the current fiscal year.

Elevance Health Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 25th. Investors of record on Tuesday, March 10th will be given a dividend of $1.72 per share. The ex-dividend date of this dividend is Tuesday, March 10th. This is a boost from Elevance Health's previous quarterly dividend of $1.71. This represents a $6.88 dividend on an annualized basis and a yield of 2.4%. Elevance Health's payout ratio is presently 27.39%.

Elevance Health Profile

Elevance Health, Inc NYSE: ELV is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company's strategic focus on integrated health care and benefit delivery.

Elevance's core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.

Want to see what other hedge funds are holding ELV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elevance Health, Inc. (NYSE:ELV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.